Screener
Lexicon Pharmaceuticals LXRX Product — Net product and licensing revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Lexicon Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001062822-26-000117
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenues: | ||||
| Net product revenue | $680 | $1,322 | $1,770 | $2,584 |
| Licensing and milestone revenue | — | 27,544 | 20,000 | 27,544 |
| Royalties and other revenue | 12 | — | 24 | — |
| Total revenues | 692 | 28,866 | 21,794 | 30,128 |
| Operating expenses: | ||||
| Cost of sales | 39 | 33 | 147 | 63 |
| Research and development, including stock-based compensation of $1,384, $1,620, $2,753, and $3,194 respectively | 17,443 | 15,747 | 30,199 | 31,050 |
Item 1. Financial Statements
FAQ
- What is Lexicon Pharmaceuticals's product — net product and licensing revenue?
- Lexicon Pharmaceuticals (LXRX) reported product — net product and licensing revenue of $680K in Q2 2026.
- How has Lexicon Pharmaceuticals's product — net product and licensing revenue changed year-over-year?
- Lexicon Pharmaceuticals's product — net product and licensing revenue decreased by 48.6% year-over-year, from $1.32M to $680K.
- What is the long-term trend for Lexicon Pharmaceuticals's product — net product and licensing revenue?
- Over 2 years (2023 to 2025), Lexicon Pharmaceuticals's product — net product and licensing revenue has grown at a 104.6% compound annual growth rate (CAGR), from $1.11M to $4.65M.
- What does product — net product and licensing revenue mean?
- This metric represents the total revenue generated from the sale of pharmaceutical products and associated licensing agreements within the company's primary product segment. It reflects the commercial success and market adoption of the company's drug portfolio after accounting for returns, allowances, and rebates. Monitoring this figure is essential for evaluating the company's transition from a research-focused entity to a commercial-stage biopharmaceutical business.
Ask your AI about Lexicon Pharmaceuticals's product — net product and licensing revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude